NOVARTIS FOUNDATION SYMPOSIUM 262 - BIOLOGY OF IGF-1 - ITS INTERACTION WITH INSULIN IN HEALTH AND MALIGNANT STATES

• the definition of danger zones
• the development of methods for early recognition of malignant states linked to IGF-1 and/or insulin
• possible approaches to preventative intervention
• the relevance in this field of research to the development of novel therapeutic approaches to treating certain cancers.

Circulating IGF-I and its role in cancer: lessons from the IGF-1 gene-deletion (LID) mouse (Yakar et al).

Physiology of the IGF system (Holly).

Molecular basis of insulin action (Zick).

IGF-1 and insulin as growth hormones (Laron).

Insulin-like growth factors and neoplasia (Pollak).

Loss of IGF2 imprinting: mechanisms and consequences (Ohlsson).

Insulin and IGF-1 receptor trafficking and sginalling (Foti et al).

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb (Nobukini and Thomas).

Structural biology of insulin and IGF-1 receptors (De Meyts et al).

Genetic blockade of the insulin-like growth factor-I receptor for human malignancy (Adachi et al).

IGF-1 and prostate cancer (Roberts Jr.).

IGF-1 and breast cancer (Lonning and Helle).

IGFBPs and cancer (Fang et al).

The IGF receptor as anti-cancer treatment target (Macaulay).

Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence (Kaaks).

Final discussion.

Index of contributors.

Subject index.